Onconox Inc. Appoints Ajay Kambhampati as Non-Executive Director to Strengthen Strategic, Financial, and Governance Oversight

Summary

Onconox Inc. has appointed Ajay Kambhampati as a Non-Executive Director. Ajay, one of the company’s original seed investors, brings more than 25 years of experience across healthcare technology, investment, and corporate finance. His strategic, financial, and operational expertise will support Onconox as it advances OCN001 through IND-enabling development and toward future clinical evaluation.

Onconox Inc., a biotechnology company advancing a novel therapeutic candidate for lung cancer, today announced the appointment of Ajay Kambhampati to its Board of Directors as a Non-Executive Director. Ajay joins the Board at a critical time for the organization as it continues progressing OCN001 through the remaining IND-enabling activities and preparing for future clinical development.

Ajay brings more than 25 years of experience across healthcare technology, investment, and corporate finance. He currently serves as Treasurer of Onconox, overseeing financial strategy, capital planning, and corporate operations. Prior to joining the Board, Ajay was one of Onconox’s original seed investors, recognizing the scientific potential of OCN001 and the strength of the early regulatory and preclinical progress achieved. His involvement from inception reflects a deep commitment to the company’s mission and long-term value creation.

His career includes leadership roles in multiple healthcare and technology companies, execution of complex M&A transactions, and hands-on support for high-growth ventures. He has also served as an active mentor and investor in early-stage life science and digital health businesses, guiding teams on capital deployment, operational discipline, and sustainable scaling. This experience enhances Onconox’s governance framework and reinforces its commitment to disciplined financial and strategic oversight.

Dr Sitaram Velaga, CEO of Onconox Inc., commented:"Ajay’s combination of strategic insight, financial expertise, and early belief in our mission makes him an outstanding addition to the Board. His guidance will be invaluable as we advance OCN001 toward the clinic and continue strengthening the foundations of the company."

Ajay Kambhampati added:"Having supported Onconox from its earliest days, I am pleased to formalize my role on the Board. The company has made tremendous progress, and I look forward to working closely with Sitaram and the team to support OCN001’s advancement and help shape the next phase of growth."

Ajay’s appointment further solidifies the company’s governance and leadership structure, following its successful seed round, strategic advisory appointments, and continued scientific and regulatory progress.

Further updates will be provided as the company advances toward key development milestones.